Spinogenix publishes reports and posters of our research which you can view below.

Rapid and Durable Improvements in Cognitive and Neurophysiological Outcomes in mild-to-moderate AD patients treated with the synaptic regenerative drug, Tazbentetol

Publication: AAIC
Date: 2026

View Poster

SPG601-associated modulation of resting-state EEG and improvement in executive function in a fragile X syndrome randomized controlled crossover study

Publication: Scientific Reports
Date: 2026

View Report

Phase 2a Topline Clinical Results Evaluating Neurophysiological and Functional Measures in SPG302-treated ALS Participants

Publication: NEALS
Date: 2025

View Poster

Early positive signals of cognitive outcomes in mild to moderate Alzheimer patients treated with the synaptic regenerative small molecule, SPG302

Publication: AAIC
Date: 2025

View Poster